PERRONE, FEDERICA
 Distribuzione geografica
Continente #
EU - Europa 270
AS - Asia 217
NA - Nord America 164
SA - Sud America 23
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 678
Nazione #
RU - Federazione Russa 179
US - Stati Uniti d'America 149
CN - Cina 81
SG - Singapore 67
IT - Italia 29
HK - Hong Kong 24
VN - Vietnam 23
BR - Brasile 20
FR - Francia 11
CA - Canada 9
DE - Germania 8
SE - Svezia 8
GB - Regno Unito 7
TR - Turchia 7
IN - India 6
FI - Finlandia 5
MX - Messico 5
AT - Austria 4
JP - Giappone 4
NL - Olanda 4
PL - Polonia 4
ES - Italia 3
RO - Romania 3
ZA - Sudafrica 3
BD - Bangladesh 2
EC - Ecuador 2
IE - Irlanda 2
LT - Lituania 2
AR - Argentina 1
GT - Guatemala 1
OM - Oman 1
PH - Filippine 1
PK - Pakistan 1
PT - Portogallo 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 678
Città #
Singapore 35
Moscow 29
Hong Kong 24
Ashburn 20
Beijing 19
Dallas 17
San Jose 14
Ho Chi Minh City 10
Shanghai 10
Los Angeles 8
Milan 8
New York 8
Hanoi 7
Boardman 6
Hefei 6
Orem 6
Denver 5
Lauterbourg 5
Montreal 5
Santa Clara 4
São Paulo 4
Tokyo 4
Warsaw 4
Ankara 3
Chennai 3
Council Bluffs 3
Guangzhou 3
Helsinki 3
Mexico City 3
Turin 3
Amsterdam 2
Atlanta 2
Belo Horizonte 2
Bexley 2
Brooklyn 2
Chicago 2
Dublin 2
Forio 2
Frankfurt am Main 2
Guayaquil 2
Johannesburg 2
Mumbai 2
Nuremberg 2
Phoenix 2
Sant'Antimo 2
Seattle 2
Shenzhen 2
Stockholm 2
Tianjin 2
Toronto 2
Vienna 2
Xi'an 2
Amargosa 1
Araçatuba 1
Augsburg 1
Biên Hòa 1
Bovisio-Masciago 1
Buffalo 1
Bắc Ninh 1
Calgary 1
Campinas 1
Charleston 1
Charlotte 1
Chihuahua City 1
City of London 1
Coroatá 1
Cà Mau 1
Delhi 1
Dhaka 1
Durban 1
Falkenstein 1
Genoa 1
Guatemala City 1
Houston 1
Ilford 1
Istanbul 1
Kayseri 1
Kilis 1
Kunming 1
Lappeenranta 1
Lawrence 1
London 1
Manchester 1
Muscat 1
München 1
Nuraminis 1
Orlando 1
Passagem Franca 1
Perris 1
Pittsburgh 1
Poplar 1
Porto 1
Praia Grande 1
Princeton 1
Pristina 1
Quanzhou 1
Querétaro 1
Querência do Norte 1
Regina 1
Rome 1
Totale 371
Nome #
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 108
Quality-of-life analysis of the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study comparing platinum-based versus non-platinum-based chemotherapy in patients with partially platinum-sensitive recurrent ovarian cancer 107
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 103
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 88
Brief Report: Canadian Cancer Trials Group IND.227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171) 78
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 70
Biomarker testing implementation for molecularly targeted therapy in non-small cell lung cancer patients 65
MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers 47
Clinical practice guidelines for the management of non-functioning advanced GEP-NENs: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology (AIOM) in collaboration with the Italian Association for Neuroendocrine Tumors (ITANET) 32
Totale 698
Categoria #
all - tutte 2.374
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.374


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221 0 0 0 0 0 0 0 1 0 0 0 0
2022/202311 3 2 1 0 0 1 2 0 2 0 0 0
2023/202434 0 1 6 4 1 4 0 2 0 1 7 8
2024/2025113 12 11 3 6 4 9 22 11 11 9 4 11
2025/2026539 35 35 17 73 56 26 48 55 159 35 0 0
Totale 698